本文選題：肝細胞癌 + 磷脂酶Cε1　； 參考：《安徽醫(yī)科大學》2017年碩士論文

【摘要】：目的:探究磷脂酶Cε1(Phospholipase C epsilon 1,PLCE1)在肝細胞癌組織中的表達及其對預后的預測價值。材料和方法:(1)收集90例行肝切除術且病理證實為肝細胞癌的組織石蠟切片標本及臨床、預后資料,采用免疫組織化學法檢測90例肝癌組織中PLCE1表達情況,統(tǒng)計分析PLCE1在肝細胞癌組織中的表達情況與肝細胞癌患者臨床病理資料特征以及預后的相關性;(2)收集20對術后病理證實為肝細胞癌患者的新鮮癌組織和癌旁組織標本,采用定量反轉錄聚合酶連鎖反應實驗(quantificational real-time polymerase chain reaction,qRT-PCR)及蛋白免疫印記實驗(western blot,WB)檢測肝細胞癌組織中PLCE1 mRNA和蛋白質的表達情況;(3)采用western blot技術檢測PLCE1在4種肝細胞癌細胞株(SK-Hep1、PLC、HepG2以及Hep3B)和正常肝細胞株(THLE3)的表達情況。結果:(1)免疫組織化學實驗結果示在90例肝細胞癌標本中,36例(40%)癌組織中PLCE1表達下調,而癌旁組織中僅17例(18.9%)(P0.05),臨床病理資料分析顯示肝癌組織中PLCE1表達下調與腫瘤包膜,血管侵犯,Edmondson分級,AFP以及TNM分期密切相關(P=0.025;P=0.006;P=0.009;P=0.011;P=0.009)。生存分析中單因素分析示PLCE1表達與肝細胞癌病人根治術后的總生存率和無瘤生存率密切相關(P0.001;P0.001),多因素分析示PLCE1是肝細胞癌術后總生存率和無瘤生存率的獨立危險因素(P0.001;P=0.003)。(2)qRT-PCR結果示20對新鮮組織標本中,17例(85%)標本癌組織中PLCE1的表達較癌旁組織明顯下調,PLCE1在癌組織和癌旁組織中的mRNA表達量分別為0.51±0.49和1.46±1.10,差異具有統(tǒng)計學意義(P=0.001)。(3)WB實驗結果顯示,在20對新鮮組織標本中,18例(90%)標本癌組織中PLCE1的表達較癌旁組織明顯下調,PLCE1在癌組織和癌旁組織中的蛋白表達量為0.93±0.39和1.22±0.40,差異具有統(tǒng)計學意義(P=0.026)。另外,通過WB實驗顯示,PLCE1蛋白在4種肝細胞癌細胞株(SK-Hep1、PLC、HepG2以及Hep3B)的表達明顯低于正常肝細胞株(THLE3)。結論:PLCE1在肝細胞癌中的表達明顯下調,與預后息息相關,可作為肝細胞癌患者預后的獨立預測指標。
[Abstract]:Objective: to investigate the expression of phospholipase C 蔚 1(Phospholipase C epsilon 1 (PLCE1) and its prognostic value in hepatocellular carcinoma (HCC). Materials and methods paraffin sections and clinical data were collected from 90 cases of hepatectomy and confirmed by pathology. The expression of PLCE1 was detected by immunohistochemical method in 90 cases of HCC. A statistical analysis of the expression of PLCE1 in hepatocellular carcinoma (HCC) and the correlation between the clinicopathological features and prognosis of HCC patients were made. Twenty pairs of fresh and paracancerous tissues proved by postoperative pathology were collected. Quantificational real-time polymerase chain reactionation qRT-PCR and Western blotWB) were used to detect the expression of PLCE1 mRNA and protein in hepatocellular carcinoma tissues using quantitative reverse transcriptase polymerase chain reaction (QRT). Western blot technique was used to detect the expression of PLCE1 mRNA and protein in four kinds of hepatocellular carcinoma (HCC). The expression of SK-Hep1 PLCG _ 2 and Hep3B) and THLE3) in normal hepatocytes. Results the immunohistochemical results showed that the expression of PLCE1 was down-regulated in 90 hepatocellular carcinoma tissues (36 / 40), but only in 17 adjacent tissues. The clinicopathological data showed that the expression of PLCE1 was down-regulated and the tumor capsule was found in HCC tissues. Edmondson grade of vascular invasion and TNM stage were closely related to P0. 025, P0. 006, P0. 009, P0. 011 and P0. 009. In survival analysis, univariate analysis showed that the expression of PLCE1 was closely related to the overall survival rate and tumor-free survival rate of patients with hepatocellular carcinoma after radical operation. Multivariate analysis showed that PLCE1 was an independent risk of overall survival and tumor-free survival after operation for hepatocellular carcinoma. The results of RT-PCR showed that the expression of PLCE1 in cancer tissues of 20 pairs of fresh tissues was significantly lower than that of adjacent tissues (0.51 鹵0.49 and 1.46 鹵1.10, respectively), and the difference was statistically significant. The expression of PLCE1 in cancer tissues was significantly lower than that in adjacent tissues (0.93 鹵0.39 and 1.22 鹵0.40, respectively), and the difference was statistically significant. In addition, the expression of PLCE1 protein in four kinds of hepatocellular carcinoma cell lines (SK-Hep1, HepG2 and Hep3B) was significantly lower than that in normal hepatocytes. Conclusion the expression of 1% PLCE1 is down-regulated in hepatocellular carcinoma, which is closely related to the prognosis. It can be used as an independent predictor of the prognosis of hepatocellular carcinoma.
【學位授予單位】：安徽醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R735.7

【參考文獻】

相關期刊論文 前3條

1 余勝;吳芳;郭坤;邵欽樹;陶厚權;;磷脂酶Cε1在胃癌組織中的表達及與胃癌患者預后的關系[J];中華胃腸外科雜志;2014年04期

2 莢衛(wèi)東;劉文斌;;高危復發(fā)因素肝細胞癌肝切除術后的綜合治療[J];世界華人消化雜志;2013年30期

3 董家鴻;黃志強;;精準肝切除——21世紀肝臟外科新理念[J];中華外科雜志;2009年21期

，

本文編號：1865523